Pharma Focus Asia

BeiGene and NewBridge Pharmaceuticals Conclude Partnership for BRUKINSA® (Zanubrutinib) in the MENA Region

Friday, June 14, 2024

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has decided to end its partnership with NewBridge Pharmaceuticals. This decision aligns with BeiGene's strategy to increase its footprint and directly oversee operations in the MENA region.

The partnership, which started in 2020, covered the sales, distribution, and marketing of BRUKINSA® (Zanubrutinib) across the MENA region. Throughout the collaboration, BRUKINSA received approval from health authorities in several areas and has been marketed in multiple regions, with additional approvals expected. The transition plan is set to unfold on a country-by-country basis, starting in June 2024 and concluding by March 31, 2025. Although the distribution agreement is set to end on March 31, 2025, BeiGene will assume all customer-facing responsibilities, including Medical Affairs, Commercial Operations, and Market Access, beginning June 11, 2024, as part of their expanded regional team.

“NewBridge Pharmaceuticals has been a key partner in our MENA operations over the past five years, and we appreciate their contributions,” stated Mohammed Al-Kapany, General Manager of the MENA region. “With the move to a direct operational model, BeiGene is dedicated to ensuring a smooth transition and enhancing cancer care by making our treatments more accessible to patients. We are committed to building on the solid groundwork established during this partnership and pursuing our global growth goals.”

Hisham El Sayed, Executive VP & Regional Head of Commercial, Middle East & Africa at NewBridge Pharmaceuticals, remarked, “Our collaboration with BeiGene has been highly productive, and we take pride in our joint accomplishments. We support BeiGene’s strategic choice and are committed to facilitating a smooth transition for the healthcare providers and patients we serve.”

This strategic move represents a significant step for BeiGene as it expands its global operations. By 2025, the company aims to make significant strides in the treatment of solid tumors and hematological cancers, demonstrating its commitment to delivering innovative cancer therapies worldwide. This transition underscores BeiGene's focus on providing advanced treatments to cancer patients across the globe.



magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference